Journal
MOLECULAR CANCER
Volume 9, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1476-4598-9-131
Keywords
-
Categories
Funding
- Alberta Cancer Foundation
- Allard Foundation
- NSERC
- Alberta Advanced Education and Technology
- US Department of Defense Breast Cancer Research Program [W81XWH-05-1-0238]
- Texas Health Science Center San Antonio, through the NCI Cancer Center [2 P30 CA054174-17]
Ask authors/readers for more resources
Background: A maximum entropy approach is proposed to predict the cytotoxic effects of a panel of colchicine derivatives in several human cancer cell lines. Data was obtained from cytotoxicity assays performed with 21 drug molecules from the same family of colchicine compounds and correlate these results with independent tubulin isoform expression measurements for several cancer cell lines. The maximum entropy method is then used in conjunction with computed relative binding energy values for each of the drug molecules against tubulin isotypes to which these compounds bind with different affinities. Results: We have found by using our analysis that alpha beta I and alpha beta III tubulin isoforms are the most important isoforms in establishing predictive response of cancer cell sensitivity to colchicine derivatives. However, since alpha beta I tubulin is widely distributed in the human body, targeting it would lead to severe adverse side effects. Consequently, we have identified tubulin isotype alpha beta III as the most important molecular target for inhibition of microtubule polymerization and hence cancer cell cytotoxicity. Tubulin isotypes alpha beta I and alpha beta II are concluded to be secondary targets. Conclusions: The benefit of being able to correlate expression levels of specific tubulin isotypes and the resultant cell death effect is that it will enable us to better understand the origin of drug resistance and hence design optimal structures for the elimination of cancer cells. The conclusion of the study described herein identifies tubulin isotype alpha beta III as a target for optimized chemotherapy drug design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available